A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study) - HAL-SHS - Sciences de l'Homme et de la Société
Article Dans Une Revue European Journal of Cancer Année : 2012

A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)

Fichier non déposé

Dates et versions

halshs-00680996 , version 1 (20-03-2012)

Identifiants

  • HAL Id : halshs-00680996 , version 1

Citer

Catherine Sebban, Anne Lefranc, Lionel Perrier, Philippe Moreau, Daniel Espinouse, et al.. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). European Journal of Cancer, 2012, 48 (5), pp. 713-720. ⟨halshs-00680996⟩
130 Consultations
0 Téléchargements

Partager

More